Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIbIIIa inhibitors
- 30 September 1995
- journal article
- review article
- Published by Elsevier in American Heart Journal
- Vol. 130 (3) , 666-672
- https://doi.org/10.1016/0002-8703(95)90304-6
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- 931-113 Demonstration of Potent Inhibition of Platelet Aggregation with an Orally Active GPllb/IIIA Receptor AntagonistJournal of the American College of Cardiology, 1995
- Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.Circulation, 1994
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 1994
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibodyThe American Journal of Cardiology, 1993
- A Comparison of Directional Atherectomy with Coronary Angioplasty in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 1993